Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

This study has been completed.

Study NCT00269412 Information provided by Salix Pharmaceuticals

First Received: December 22, 2005 Last Updated: December 6, 2007 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given